SC
ABBV icon

Schulhoff & Co’s AbbVie ABBV Stock Holding History

Schulhoff & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.99M Sell
27,560
-140
-0.5% -$31.1K 2.46% 9
2025
Q4 		$6.33M Sell
27,700
-30
-0.1% -$6.83K 2.66% 8
2025
Q3 		$6.42M Sell
27,730
-41
-0.1% -$8.35K 2.74% 8
2025
Q2 		$5.15M Buy
27,771
+130
+0.5% +$24.2K 2.29% 11
2025
Q1 		$5.79M Sell
27,641
-67
-0.2% -$13K 2.56% 9
2024
Q4 		$49.2M Sell
27,708
-110
-0.4% -$20.2K 17.97% 1
2024
Q3 		$5.49M Sell
27,818
-85
-0.3% -$15.9K 2.29% 9
2024
Q2 		$4.79M Hold
27,903
– – 2.16% 11
2024
Q1 		$5.08M Sell
27,903
-330
-1% -$56.9K 2.23% 9
2023
Q4 		$4.38M Sell
28,233
-125
-0.4% -$18.2K 2.08% 12
2023
Q3 		$4.23M Sell
28,358
-3,240
-10% -$476K 2.14% 10
2023
Q2 		$4.26M Sell
31,598
-360
-1% -$52.8K 1.98% 12
2023
Q1 		$5.09M Sell
31,958
-50
-0.2% -$7.64K 2.37% 9
2022
Q4 		$5.17M Sell
32,008
-400
-1% -$61.3K 2.38% 8
2022
Q3 		$4.35M Sell
32,408
-300
-0.9% -$43K 2.27% 10
2022
Q2 		$5.01M Sell
32,708
-30
-0.1% -$4.58K 2.34% 8
2022
Q1 		$5.31M Sell
32,738
-400
-1% -$58.1K 2.24% 13
2021
Q4 		$4.49M Buy
33,138
+200
+0.6% +$23.6K 1.85% 16
2021
Q3 		$3.55M Buy
32,938
+340
+1% +$38.9K 1.6% 19
2021
Q2 		$3.67M Buy
32,598
+1,200
+4% +$135K 1.62% 19
2021
Q1 		$3.4M Buy
31,398
+2,950
+10% +$316K 1.55% 18
2020
Q4 		$3.05M Buy
28,448
+1,035
+4% +$99.5K 1.53% 19
2020
Q3 		$2.4M Buy
27,413
+400
+1% +$37.7K 1.29% 26
2020
Q2 		$2.65M Buy
27,013
+94
+0.3% +$8.28K 1.56% 20
2020
Q1 		$2.05M Sell
26,919
-505
-2% -$43K 1.28% 24
2019
Q4 		$2.43M Buy
27,424
+350
+1% +$29.1K 1.14% 26
2019
Q3 		$2.05M Buy
27,074
+690
+3% +$47.3K 1.01% 30
2019
Q2 		$1.92M Buy
26,384
+100
+0.4% +$7.86K 0.99% 30
2019
Q1 		$2.12M Buy
26,284
+1,575
+6% +$129K 1.13% 27
2018
Q4 		$2.28M Sell
24,709
-575
-2% -$50.6K 1.42% 22
2018
Q3 		$2.39M Buy
25,284
+480
+2% +$45.5K 1.34% 23
2018
Q2 		$2.3M Buy
24,804
+815
+3% +$79.6K 1.37% 22
2018
Q1 		$2.27M Buy
23,989
+57
+0.2% +$6.26K 1.33% 21
2017
Q4 		$2.31M Buy
23,932
+20
+0.1% +$1.89K 1.3% 21
2017
Q3 		$2.12M Hold
23,912
– – 1.26% 21
2017
Q2 		$1.73M Buy
23,912
+60
+0.3% +$4.03K 1.06% 27
2017
Q1 		$1.55M Buy
23,852
+610
+3% +$38.4K 0.96% 31
2016
Q4 		$1.46M Buy
23,242
+597
+3% +$36.4K 0.89% 33
2016
Q3 		$1.43M Buy
22,645
+500
+2% +$32.4K 0.88% 36
2016
Q2 		$1.37M Buy
22,145
+705
+3% +$43K 0.85% 35
2016
Q1 		$1.22M Buy
21,440
+200
+0.9% +$11.1K 0.8% 38
2015
Q4 		$1.26M Hold
21,240
– – 0.85% 36
2015
Q3 		$1.16M Sell
21,240
-3,007
-12% -$196K 0.83% 36
2015
Q2 		$1.63M Buy
24,247
+400
+2% +$26.1K 1.04% 30
2015
Q1 		$1.4M Buy
23,847
+151
+0.6% +$9.12K 0.87% 34
2014
Q4 		$1.55M Hold
23,696
– – 0.93% 30
2014
Q3 		$1.37M Sell
23,696
-34
-0.1% -$1.89K 0.85% 33
2014
Q2 		$1.34M Buy
23,730
+2,360
+11% +$124K 0.83% 35
2014
Q1 		$1.1M Buy
21,370
+165
+0.8% +$8.34K 0.74% 33
2013
Q4 		$1.12M Buy
21,205
+100
+0.5% +$4.92K 0.77% 35
2013
Q3 		$944K Buy
21,105
+400
+2% +$17.7K 0.68% 37
2013
Q2 		$856K Buy
+20,705
New +$906K 0.65% 36

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schulhoff & Co's ABBV Position: Q1 2026 in Review

Schulhoff & Co reduced its AbbVie (ABBV) stake by 0.51% in Q1 2026, selling an estimated $31.1K and leaving 27,560 shares worth $5.99M. The position accounts for 2.46% of the portfolio, ranked #9.

Schulhoff & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $49.2M in Q4 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Schulhoff & Co held 27,560 shares of AbbVie worth $5.99M as of Q1 2026.
  • Schulhoff & Co sold 140 AbbVie shares in Q1 2026, an estimated $31.1K.
  • AbbVie made up 2.46% of Schulhoff & Co's portfolio in Q1 2026, its #9 holding.
  • Schulhoff & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Schulhoff & Co's AbbVie position peaked at $49.2M in Q4 2024.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Schulhoff & Co's 13F filing for Q1 2026, filed 11 May 2026.